Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief

This article was originally published in The Tan Sheet

Executive Summary

Robinson steps up to drug production; no warning needed for St. John’s wort, CRN says; Iovate settles with Calif. counties; more In Brief

You may also be interested in...

“Devil Is In The Details” On Prop 65 Reform Benefits – AHPA

California Governor Jerry Brown proposes to tweak Proposition 65 to reduce the number of frivolous lawsuits against small businesses. More than 10% of Prop 65 litigation targets since 2008 have been supplement firms, says the American Herbal Products Association.

In Brief

Novartis OTC plant not “out of the woods”; ERSP questions Calmestra claims; GSK seeks to switch Pirinase Hayfever Relief to GSL in U.K.; Kaneka raises CoQ10 prices; FTC to disburse consumer refund for Iovate supplements; more In brief.

California GMO Labeling Initiative Threatens Supplements

A California ballot initiative to require labeling of genetically modified foods would be a “nightmare” for supplement manufacturers, says NAI CEO Mark LeDoux. CRN President Steve Mister advocates educating consumers about GMO.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts